Issue Date: March 13, 2017
Sanofi, AstraZeneca in respiratory deal
Sanofi Pasteur and MedImmune, the biologics arm of AstraZeneca, have agreed to develop MED18897, a monoclonal antibody, for the prevention of lower respiratory tract illness caused by respiratory syncytial virus. MED18897 is currently in a Phase II clinical trial involving infants ineligible for Synagis, the current standard of care. Sanofi Pasteur will make an up-front payment of $127 million to MedImmune and milestone payments of up to $523 million.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society